Overview

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Status:
Recruiting

Trial end date:
2030-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the objective response of GB1211 and pembrolizumab versus pembrolizumab and placebo in patients with advance metastatic melanoma or head and neck squamous cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Providence Health & Services

Collaborators:

Galecto Biotech AB
Providence Cancer Center
Providence Cancer Center, Earle A. Chiles Research Institute

Treatments:

Pembrolizumab